What is Cytodyn Inc's earnings per share (EPS)?

Cytodyn Inc (CYDY) reported diluted earnings per share of $0.00 for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cytodyn Inc Financials

CYDY

Source SEC Filings (10-K/10-Q) Updated Nov 30, 2025 Currency USD FYE May

This page shows Cytodyn Inc (CYDY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

Cytodyn Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

-2.34x

For every $1 of reported earnings, Cytodyn Inc generates $-2.34 in operating cash flow (-$8.8M OCF vs $3.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

$9.7M

YoY+153.7%

Cytodyn Inc's EBITDA was $9.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 153.7% from the prior year.

Net Income

$3.7M

YoY+107.5%

Cytodyn Inc reported $3.7M in net income in fiscal year 2025. This represents an increase of 107.5% from the prior year.

EPS (Diluted)

$0.00

YoY+100.0%

Cytodyn Inc earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$11.9M

YoY+282.7%

5Y CAGR-3.6%

10Y CAGR+9.3%

Cytodyn Inc held $11.9M in cash against $45.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

1.25B

YoY+3.0%

5Y CAGR+17.1%

10Y CAGR+36.5%

Cytodyn Inc had 1.25B shares outstanding in fiscal year 2025. This represents an increase of 3.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

CYDY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$0-100.0%	$266K	$0	N/A
Cost of Revenue	N/A	N/A	N/A	$53K	N/A	N/A
Gross Profit	N/A	N/A	N/A	$213K	N/A	N/A
R&D Expenses	N/A	$7.2M+175.1%	$2.6M-90.3%	$27.0M-49.4%	$53.4M+1.4%	$52.6M
SG&A Expenses	$7.3M-32.9%	$10.8M-36.9%	$17.1M-61.3%	$44.3M+29.1%	$34.3M+71.8%	$20.0M
Operating Income	$9.7M+153.5%	-$18.1M+55.5%	-$40.6M+72.1%	-$145.4M-39.0%	-$104.6M-40.1%	-$74.6M
Interest Expense	N/A	$31.8M-19.0%	$39.2M-40.0%	$65.4M-9.0%	$71.9M+294.5%	$18.2M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	$3.7M+107.5%	-$49.8M+37.6%	-$79.8M+62.1%	-$210.8M-19.5%	-$176.5M-26.1%	-$139.9M
EPS (Diluted)	$0.00+100.0%	$-0.05+50.0%	$-0.10+67.7%	$-0.31-3.3%	$-0.30+9.1%	$-0.33

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$650K
SG&A Expenses	$1.8M+5.0%	$1.7M	N/A	$1.5M-34.2%	$2.3M+42.8%	$1.6M	N/A	$2.8M
Operating Income	-$21.7M-338.6%	-$4.9M	N/A	-$4.0M-8.0%	-$3.7M-116.5%	$22.4M	N/A	-$3.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$8.5M
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$22.6M-308.1%	-$5.5M	N/A	-$4.8M+0.2%	-$4.8M-124.8%	$19.2M	N/A	-$11.9M
EPS (Diluted)	$-0.02	$0.00	N/A	$0.00	$0.00-100.0%	$0.02	N/A	$-0.01

CYDY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$18.0M+62.1%	$11.1M-1.4%	$11.3M-61.3%	$29.2M-77.9%	$132.1M+161.5%	$50.5M
Current Assets	$17.9M+65.3%	$10.8M+0.1%	$10.8M+2.8%	$10.5M-70.9%	$36.1M-2.0%	$36.8M
Cash & Equivalents	$11.9M+282.7%	$3.1M+22.4%	$2.5M-39.9%	$4.2M-87.5%	$33.9M+137.7%	$14.3M
Inventory	N/A	$0	$0	N/A	$93.5M+388.2%	$19.1M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$114.1M-10.8%	$127.9M+5.9%	$120.8M-2.3%	$123.6M-19.3%	$153.1M+188.9%	$53.0M
Current Liabilities	$70.5M-16.2%	$84.2M-29.7%	$119.8M-2.7%	$123.2M-19.3%	$152.5M+242.8%	$44.5M
Long-Term Debt	$45.4M+0.7%	$45.0M-1.6%	$45.7M+8.3%	$42.2M0.0%	$42.2M	N/A
Total Equity	-$96.0M+17.7%	-$116.8M-6.6%	-$109.5M-16.0%	-$94.4M-349.1%	-$21.0M-747.2%	-$2.5M
Retained Earnings	-$887.8M+0.4%	-$891.5M-5.9%	-$841.7M-9.9%	-$766.1M-38.4%	-$553.7M-47.5%	-$375.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$8.9M-33.7%	$13.5M-25.3%	$18.0M-14.8%	$21.2M-14.8%	$24.9M-11.2%	$28.0M+151.6%	$11.1M+8.4%	$10.3M
Current Assets	$8.8M-33.8%	$13.3M-25.3%	$17.9M-14.8%	$21.0M-14.8%	$24.6M-11.2%	$27.7M+156.5%	$10.8M+9.1%	$9.9M
Cash & Equivalents	$5.0M-46.6%	$9.3M-21.6%	$11.9M-27.4%	$16.4M-23.1%	$21.3M-14.4%	$24.9M+701.3%	$3.1M+121.5%	$1.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$128.7M+13.9%	$113.0M-1.0%	$114.1M-0.1%	$114.2M-0.1%	$114.3M+0.9%	$113.2M-11.5%	$127.9M-1.4%	$129.7M
Current Liabilities	$85.1M+22.6%	$69.4M-1.6%	$70.5M-0.1%	$70.6M-0.1%	$70.6M+1.5%	$69.6M-17.4%	$84.2M-35.0%	$129.5M
Long-Term Debt	$42.2M-3.7%	$43.8M-3.5%	$45.4M-1.1%	$45.8M-0.5%	$46.1M+1.7%	$45.3M+0.6%	$45.0M+1.7%	$44.2M
Total Equity	-$119.7M-20.3%	-$99.5M-3.6%	-$96.0M-3.3%	-$93.0M-4.0%	-$89.4M-4.9%	-$85.2M+27.0%	-$116.8M+2.2%	-$119.4M
Retained Earnings	-$915.9M-2.5%	-$893.3M-0.6%	-$887.8M-0.7%	-$881.8M-0.5%	-$877.1M-0.5%	-$872.3M+2.2%	-$891.5M-1.9%	-$874.7M

CYDY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.8M+20.2%	-$11.0M+56.3%	-$25.1M+67.7%	-$77.7M+33.9%	-$117.6M-70.9%	-$68.8M
Capital Expenditures	N/A	N/A	N/A	N/A	$122K+197.6%	$41K
Free Cash Flow	N/A	N/A	N/A	N/A	-$117.7M-71.0%	-$68.8M
Investing Cash Flow	N/A	N/A	N/A	N/A	-$122K-197.6%	-$41K
Financing Cash Flow	$10.9M-7.6%	$11.7M-60.7%	$29.9M-37.7%	$48.0M-65.0%	$137.3M+72.4%	$79.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$4.3M-77.6%	-$2.5M+56.7%	-$5.7M-14.3%	-$5.0M-38.2%	-$3.6M-165.9%	$5.4M+429.7%	-$1.6M+29.3%	-$2.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$0+100.0%	-$121K-110.4%	$1.2M+5452.4%	$21K	$0-100.0%	$9.7M+180.9%	$3.4M-5.3%	$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CYDY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	80.1%	N/A	N/A
Operating Margin	N/A	N/A	N/A	-54663.2%	N/A	N/A
Net Margin	N/A	N/A	N/A	-79255.6%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	20.8%+468.3pp	-447.6%+259.3pp	-706.9%+15.5pp	-722.4%-588.8pp	-133.6%+143.4pp	-277.0%
Current Ratio	0.25+0.1	0.13+0.0	0.090.0	0.09-0.2	0.24-0.6	0.83
Debt-to-Equity	-0.47-0.1	-0.39+0.0	-0.42+0.0	-0.45+1.6	-2.01+19.4	-21.36
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-253.0%-211.9pp	-41.1%	N/A	-22.4%-3.3pp	-19.2%-87.8pp	68.6%	N/A	-116.1%
Current Ratio	0.10-0.1	0.19-0.1	0.25-0.0	0.30-0.1	0.35-0.0	0.40+0.3	0.13+0.1	0.08
Debt-to-Equity	-0.35+0.1	-0.44+0.0	-0.47+0.0	-0.49+0.0	-0.52+0.0	-0.53-0.1	-0.39-0.0	-0.37
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$96.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.25), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Northwest Bio NWBO

$308.1M

Clinuvl Phrmaceu CLVLY

$367.1M

Nervgen Pharma Corp NGENF

$446.0M

Hansa Medical AB HNSBF

$371.7M

Genus Plc GENSY

$2.0B

Frequently Asked Questions

Is Cytodyn Inc profitable?

Yes, Cytodyn Inc (CYDY) reported a net income of $3.7M in fiscal year 2025.

What is Cytodyn Inc's EBITDA?

Cytodyn Inc (CYDY) had EBITDA of $9.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cytodyn Inc have?

As of fiscal year 2025, Cytodyn Inc (CYDY) had $11.9M in cash and equivalents against $45.4M in long-term debt.

What is Cytodyn Inc's operating cash flow?

Cytodyn Inc (CYDY) generated -$8.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cytodyn Inc's total assets?

Cytodyn Inc (CYDY) had $18.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Cytodyn Inc have outstanding?

Cytodyn Inc (CYDY) had 1.25B shares outstanding as of fiscal year 2025.

What is Cytodyn Inc's current ratio?

Cytodyn Inc (CYDY) had a current ratio of 0.25 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Cytodyn Inc's debt-to-equity ratio?

Cytodyn Inc (CYDY) had a debt-to-equity ratio of -0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cytodyn Inc's return on assets (ROA)?

Cytodyn Inc (CYDY) had a return on assets of 20.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cytodyn Inc's cash runway?

Based on fiscal year 2025 data, Cytodyn Inc (CYDY) had $11.9M in cash against an annual operating cash burn of $8.8M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Cytodyn Inc's debt-to-equity ratio negative or unusual?

Cytodyn Inc (CYDY) has negative shareholder equity of -$96.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Cytodyn Inc's Piotroski F-Score?

Cytodyn Inc (CYDY) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cytodyn Inc's earnings high quality?

Cytodyn Inc (CYDY) has an earnings quality ratio of -2.34x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.